| Cover | Jul. 05, 2022 |
| Cover [Abstract] | |
| Document Type | 8-K |
| Amendment Flag | false |
| Document Period End Date | Jul. 05, 2022 |
| Current Fiscal Year End Date | --12-31 |
| Entity File Number | 001-13341 |
| Entity Registrant Name | Titan Pharmaceuticals, Inc. |
| Entity Central Index Key | 0000910267 |
| Entity Tax Identification Number | 94-3171940 |
| Entity Incorporation, State or Country Code | DE |
| Entity Address, Address Line One | 400 Oyster Point Blvd. |
| Entity Address, Address Line Two | Suite 505 |
| Entity Address, City or Town | South San Francisco |
| Entity Address, State or Province | CA |
| Entity Address, Postal Zip Code | 94080 |
| City Area Code | 650 |
| Local Phone Number | 244-4990 |
| Written Communications | false |
| Soliciting Material | false |
| Pre-commencement Tender Offer | false |
| Pre-commencement Issuer Tender Offer | false |
| Title of 12(b) Security | Common Stock, $0.001 par value |
| Trading Symbol | TTNP |
| Security Exchange Name | NASDAQ |
| Entity Emerging Growth Company | false |
